GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

Liselotte van Bloemendaal,Richard G. IJzerman,Jennifer S. ten Kulve,Frederik Barkhof,Robert J. Konrad,Madeleine L. Drent,Dick J. Veltman,Michaela Diamant

DOI: https://doi.org/10.2337/db14-0849

IF: 7.7

2014-11-13

Diabetes

Abstract:Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetite- and reward-related brain areas. Obese T2DM patients and normoglycemic obese and lean individuals (n = 48) were studied in a randomized, crossover, placebo-controlled trial. Using functional MRI, we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin 9-39, on brain responses to food pictures during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycemic obese versus lean subjects showed increased brain responses to food pictures in appetite- and reward-related brain regions (insula and amygdala). Exenatide versus placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen, and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin 9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether GLP - 1 (glucagon - like peptide - 1) receptor activation reduces food intake by regulating brain regions related to appetite and reward. Specifically, the researchers hypothesized that GLP - 1 receptor agonists reduce food intake by affecting the areas in the brain that control appetite and reward, and this effect is mediated by GLP - 1 receptors, independent of other hormones or metabolic changes.

### Research Background

The increasing global incidence of obesity and type 2 diabetes mellitus (T2DM) has become a major public health problem. Studies have shown that overeating may be related to changes in the central nervous system (CNS) response to satiety and reward of food, similar to the CNS response changes in drug addiction. GLP - 1 is a hormone secreted by the intestine, which can stimulate postprandial insulin secretion, inhibit glucagon release and delay gastric emptying, thereby improving blood - glucose control. In addition, GLP - 1 is also considered to play a role in regulating food intake.

### Research Purpose

The main purpose of this study was to evaluate the effects of GLP - 1 receptor agonists (such as exenatide) on brain responses and food intake in obese T2DM patients, normoglycemic obese individuals and lean individuals. To exclude the interference of other hormonal or metabolic changes caused by GLP - 1 receptor activation, all measurements were carried out under the pancreatic - pituitary clamp state using somatostatin.

### Main Findings

1. **Brain Region Activation**: In obese individuals and T2DM patients, the activation of brain regions related to appetite and reward (such as the insula and amygdala) increased when viewing food pictures.
2. **Effect of GLP - 1 Receptor Agonists**: Exenatide significantly reduced food intake in T2DM patients and obese individuals, and decreased food - related brain responses in regions such as the insula, amygdala, putamen and orbitofrontal cortex in these individuals.
3. **Effect of GLP - 1 Receptor Antagonists**: Pretreatment with GLP - 1 receptor antagonists (such as exendin9 - 39) could block the above - mentioned effects of exenatide, indicating that these effects are mediated by GLP - 1 receptors.

### Conclusion

This study provides new insights, revealing how GLP - 1 receptor agonists reduce food intake by affecting brain regions related to appetite and reward, which in turn leads to weight loss. This mechanism provides a theoretical basis for the development of new therapies for obesity and type 2 diabetes.

Through this study, the authors verified the hypothesis that GLP - 1 receptor agonists reduce food intake by regulating regions in the brain related to appetite and reward, and proved that this effect is GLP - 1 receptor - mediated, independent of other metabolic and hormonal changes.